Dermatologie

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives⁸.

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Written by Anna Ekman, Medical Lead North Europe at Sanofi

Dupixent is de eerste en enige modulerende behandeling specifiek gericht op IL-4 en IL-13, die in belangrijke mate verantwoordelijk zijn voor de onderliggende chronische type 2 inflammatie in prurigo nodularis.¹

Dupixent is de eerste en enige modulerende behandeling specifiek gericht op IL-4 en IL-13, die in belangrijke mate verantwoordelijk zijn voor de onderliggende chronische type 2 inflammatie.^1,2